title: Vaccine administration and the development of immune thrombocytopenic purpura in children.
abstract: The most important reasons cited by the opponents of vaccines are concerns about vaccine safety. Unlike issues such as autism for which no indisputable documentation of direct relationship with vaccine use is available, immune thrombocytopenic purpura (ITP) is an adverse event that can really follow vaccine administration, and may limit vaccine use because little is known about which vaccines it may follow, its real incidence and severity, the risk of chronic disease, or the possibility of recurrences after new doses of the same vaccine. The main aim of this review is to clarify the real importance of thrombocytopenia as an adverse event and discuss how it may interfere with recommended vaccination schedules. The available data clearly indicate that ITP is very rare and the only vaccine for which there is a demonstrated cause-effect relationship is the measles, mumps and rubella (MMR) vaccine that can occur in 1 to 3 children every 100,000 vaccine doses. However, also in this case, the incidence of ITP is significantly lower than that observed during the natural diseases that the vaccine prevents. Consequently, ITP cannot be considered a problem limiting vaccine use except in the case of children suffering from chronic ITP who have to receive MMR vaccine. In these subjects, the risk-benefit ratio of the vaccine should be weighed against the risk of measles in the community.
authors: Division of Pediatric Hematology and Oncology; Department of Hematology; Santo Spirito Hospital; Pescara, Italy.
authors: Valerio
authors: V
authors: Cecinati
authors: Nicola
authors: N
authors: Principi
authors: Letizia
authors: L
authors: Brescia
authors: Paola
authors: P
authors: Giordano
authors: Susanna
authors: S
authors: Esposito
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage* / Q000009:adverse effects*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced* / Q000453:epidemiology* / Q000473:pathology
chemical_list: D022542:Measles-Mumps-Rubella Vaccine
keywords: MMR; adverse events; immune thrombocytopenic purpura; platelets; vaccine; vaccine safety